Warby Parker Inc.
WRBYHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Warby Parker Inc. focuses on Medical Instruments & Supplies services and products. Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada. At a $3.15B market cap, Warby Parker Inc. ranks as a mid-cap company within healthcare. The company offers eyeglasses and sunglasses; and single-vision, progressive, light-responsive, polarized, blue-light-filtering, tinted, non-prescription, and contact lenses.
Market Cap
$3.15B
Beta
1.96
P/E (TTM)
2568.00
P/E (Fwd)
38.12
EPS (TTM)
$0.01
EPS (Fwd)
$0.67
ROE
0.4%
ROA
-0.5%
Cash
$288.2M
Total Debt
$237.6M
Free CF
$32.3M
52W Change
23.7%
Annual Financials
Cash vs Debt
With $288.2M in cash and $237.6M in debt, WRBY maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $32.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 0.4%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $598.1M (2022) to $871.9M (2025), reflecting a 46% increase over the period.
A beta of 1.96 means WRBY is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing WRBY.